Central Lab Services/Clinical Trial Lab Services Companies

The global central lab services/clinical trial lab services market, valued at US$5.65B in 2024, is forecasted to grow at a 6.5% CAGR, reaching US$5.97B by 2025 and US$8.18B by 2030.

Central lab clinical trial services provide essential support for pharmaceutical and biotech companies conducting clinical trials. These labs handle the collection, processing, and testing of biological samples like blood, urine, and tissues from trial participants. They ensure the accuracy and reliability of test results, which are crucial for assessing the safety and efficacy of new treatments. Central labs help maintain consistency across trial sites, offering services like chemistry tests, microbiology, genetic analysis, and immunology. By adhering to strict regulatory standards, central lab services play a key role in the success of clinical trials and the approval of new drugs or therapies.

To know about the assumptions considered for the study download the pdf brochure

Some of the prominent players operating in the market include Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Société Générale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), REPROCELL Inc. (Japan),ACM Global Laboratories (US), and among others.

Market Ranking:

The ranking of the companies in the Central lab services/clinical trial lab services market has been determined through a market share analysis, conducted after thorough secondary research and validated by primary respondents. This ranking considers parameters such as revenue generated from clinical trial lab services, innovation, and approvals and launches. Based on this analysis, the top three players leading the market are Thermo Fisher Scientific Inc. (US), IQVIA (US) and ICON plc (Ireland). These companies dominate due to their strong market presence, extensive product portfolios, and continuous innovation in Central lab services/clinical trial lab services market.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is the top provider of scientific services globally for hospitals, clinical diagnostic labs, universities, research institutes, government agencies, pharmaceutical & biotech firms, and the environmental, industrial, R&D, quality, and process control sectors. It offers new technologies and pharma services through its Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services,
Patheon, and PPD brands. The company operates through four business segments: laboratory products and biopharma services, life sciences solutions, specialty diagnostics, and analytical instruments. In December 2021, Fisher Scientific acquired PPD. Inc. for about USD 16 billion, which enabled Thermo Fisher Scientific to provide customers with clinical research services. PPD is now part of Fisher Scientific's Laboratory Products and Biopharma Services segment.

The company operates in —50 countries across the Americas, the APAC, and the EMEA Some of its subsidiaries are Fisher Clinical Services Inc. (US), Fisher Clinical Services Holding GmbH (Switzerland), Fisher Clinical Services UK Ltd. (UK), Fisher Clinical Services Holding Pte Ltd. (Singapore), PPD South Africa, PPD (New Zealand), Accelerated Enrollment Solutions (China), and PPD-SNBL (Japan).

IQVIA (US)

IQVIA was formed through the merger of Quintiles Transnational Holdings (US) and IMS Health (US) in October 2016. The company provides development and commercial outsourcing services to biopharmaceutical and contract sales & medical solutions companies. It operates through three major segments Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Research & Development Solutions segment deals with clinical development activities inlcuidng laboratory services from preclinical testing to post-launch monitoring for biopharmaceutical, pharmaceutical, and medical device companies; government & non-government organizations; and generic & biosimilar customers.

It operates in —100 countries across North America, Europe, Asia, Latin America, and Africa. Some of its subsidiaries are AIT Bioscience (US), Research Network (Shanghai) Co., Ltd. (China), Clintec CRO Services Private Limited (India), and Ireland International Research Limited (Ireland).

ICON plc (Ireland)

ICON plc offers outsourced drug development services to the pharmaceutical, biotechnology, and medical device industries. The company provides clinical, consulting, and commercial services ranging from trial design to post-market commercialization. It also provides services for clinical development processes such as clinical trial management, biometric activities, consulting, imaging, contract staffing, informatics, and laboratory services.

In April 2018, ICON rebranded its acquired ClinicalRM division into ICON Government and Public Health Solutions (GPHS). GHPS provides full-service clinical development and staffing services across multiple US government agencies, global non-government organizations (NGOs), academic institutions, and others in the global health space. In July 2021, ICON acquired PRA Health Sciences for about USD 12 billion.

According to the deal, PRA Health Sciences became a wholly owned unit of ICON. The company operates in 111 locations across 53 countries worldwide. Its subsidiaries are ICON Clinical Research PTY Limited (Australia), ICON Clinical Research (Canada) Inc., ICON Clinical Research (Beijing) Co., Ltd_ (China), ICON Clinical Research (France), and ICON Clinical Research India Private Limited.

Related Reports:

Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com